US2023227810A1PendingUtilityA1
Methods for generating barcoded combinatorial libraries
Est. expiryJun 24, 2036(~9.9 yrs left)· nominal 20-yr term from priority
Inventors:Ryan T. GillAndrew GarstTanya Elizabeth Warnecke LipscombMarcelo Colika BassaloRamsey Ibrahim Zeitoun
C12N 2310/20C12N 15/1065C12N 15/11C12N 15/102C12N 15/1082C12N 15/1079
82
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Provided herein are methods and composition for trackable genetic variant libraries. Further provided herein are methods and compositions for recursive engineering. Further provided herein are methods and compositions for multiplex engineering. Further provided herein are methods and compositions for enriching for editing and trackable engineered sequences and cells using nucleic acid-guided nucleases.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A composition comprising:
i) a first donor nucleic acid comprising:
a) a modified first target nucleic acid sequence;
b) a first protospacer adjacent motif (PAM) mutation; and
c) a first guide nucleic acid sequence comprising a first spacer region complementary to a portion of the first target nucleic acid; and
ii) a second donor nucleic acid comprising:
a) a barcode corresponding to the modified first target nucleic acid sequence; and
b) a second guide nucleic acid sequence comprising a second spacer region complementary to a portion of a second target nucleic acid.
2 . The composition of claim 1 , wherein the modified first target nucleic acid sequence comprises at least one inserted, deleted, or substituted nucleic acid compared to a corresponding un-modified first target nucleic acid.
3 . The composition of claim 1 , wherein the first guide nucleic acid and second guide nucleic acid are compatible with a nucleic acid-guided nuclease.
4 . The composition of claim 3 , wherein the nucleic acid-guided nuclease is a Type II or Type V Cas protein.
5 . The composition of claim 3 , wherein the nucleic acid-guided nuclease is a Cas9 homologue or a Cpf1 homologue.
6 . The composition of claim 1 , wherein the second donor nucleic acid comprises a second PAM mutation.
7 . The composition of claim 1 , wherein the second donor nucleic acid sequence comprises a regulatory sequence or a mutation to turn a screenable or selectable marker on or off.
8 . The composition of claim 1 , wherein the second donor nucleic acid sequence targets a unique landing site.
9 . A method of genome engineering, the method comprising:
a) contacting a population of cells with a polynucleotide, wherein each cell comprises a first target nucleic acid, a second target nucleic acid, and a nucleic acid-guided nuclease,
wherein the polynucleotide comprises
1) an editing cassette comprising:
i) a modified first target nucleic acid sequence;
ii) a first protospacer adjacent motif (PAM) mutation;
iii) a first guide nucleic acid sequence comprising a spacer region complementary to a portion of the first target nucleic acid and compatible with the nucleic acid-guided nuclease; and
2) a recorder cassette comprising
i) a barcode corresponding to the modified first target nucleic acid sequence; and
ii) a second guide nucleic acid sequence comprising a second spacer region complementary to a portion of the second target nucleic acid and compatible with the nucleic acid-guided nuclease;
b) allowing the first guide nucleic acid sequence, the second guide nucleic acid sequence, and the nucleic acid-guided nuclease to create a genome edit within the first target nucleic acid and the second target nucleic acid.
10 . The method of claim 9 , further comprising c) sequencing a portion of the barcode, thereby identifying the modified first target nucleic acid that was inserted within the first target nucleic acid in step a).
11 . The method of claim 9 , wherein the nucleic acid-guided nuclease is a CRISPR nuclease.
12 . The method of claim 9 , wherein the PAM mutation is not recognized by the nucleic acid-guided nuclease.
13 . The method of claim 9 , wherein the nucleic acid-guided nuclease is a Type II or Type V Cas protein.
14 . The method of claim 9 , wherein the nucleic acid-guided nuclease is a Cas9 homologue or a Cpf1 homologue.
15 . The method of claim 9 , wherein the recorder cassette further comprises a second PAM mutation that is not recognized by the nucleic acid-guided nuclease.
16 . A method of selectable recursive genetic engineering comprising
a) contacting cells comprising a nucleic acid-guided nuclease with a polynucleotide comprising a recorder cassette, said recorder cassette comprising
i) a nucleic acid sequence that recombines into a unique landing site incorporated during a previous round of engineering, wherein the nucleic acid sequence comprises a unique barcode; and
ii) a guide RNA compatible with the nucleic acid-guided nuclease that targets the unique landing site; and
b) allowing the nucleic acid-guided nuclease to edit the unique landing site, thereby incorporating the unique barcode into the unique landing site.
17 . The method of claim 16 , wherein the nucleic acid sequence further comprises a regulatory sequence that turns transcription of a screenable or selectable marker on or off.
18 . The method of claim 16 , wherein the nucleic acid sequence further comprises a PAM mutation that is not compatible with the nucleic acid-guided nuclease.
19 . The method of claim 16 , wherein the nucleic acid sequence further comprises a second unique landing site for subsequent engineering rounds.
20 . The method of claim 16 , wherein the polynucleotide further comprises an editing cassette comprising
a) a modified first target nucleic acid sequence; b) a first protospacer adjacent motif (PAM) mutation; and c) a first guide nucleic acid sequence comprising a first spacer region complementary to a portion of the first target nucleic acid,
wherein the unique barcode corresponds to the modified first target nucleic acid such that the modified target nucleic acid can be identified by the unique barcode.Join the waitlist — get patent alerts
Track US2023227810A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.